Business Description
Laboratory Corp of America Holdings
NAICS : 621511
SIC : 8071
Description
Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.07 | |||||
| Equity-to-Asset | 0.51 | |||||
| Debt-to-Equity | 0.62 | |||||
| Debt-to-EBITDA | 2.05 | |||||
| Interest Coverage | 14.37 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 3.44 | |||||
| Beneish M-Score | -2.4 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 14.4 | |||||
| 3-Year EBITDA Growth Rate | 27.7 | |||||
| 3-Year EPS without NRI Growth Rate | 41.5 | |||||
| 3-Year FCF Growth Rate | 44.4 | |||||
| 3-Year Book Growth Rate | 16.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -2.03 | |||||
| Future 3-5Y Total Revenue Growth Rate | 2.19 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 100 | |||||
| 9-Day RSI | 98.89 | |||||
| 14-Day RSI | 91.23 | |||||
| 6-1 Month Momentum % | -4.81 | |||||
| 12-1 Month Momentum % | -23.98 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.73 | |||||
| Quick Ratio | 1.55 | |||||
| Cash Ratio | 0.16 | |||||
| Days Inventory | 15.04 | |||||
| Days Sales Outstanding | 53.66 | |||||
| Days Payable | 23.95 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.93 | |||||
| Dividend Payout Ratio | 0.08 | |||||
| Forward Dividend Yield % | 1.19 | |||||
| 5-Year Yield-on-Cost % | 0.93 | |||||
| 3-Year Average Share Buyback Ratio | 2 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 31.39 | |||||
| Operating Margin % | 16.35 | |||||
| Net Margin % | 11.51 | |||||
| ROE % | 16.88 | |||||
| ROA % | 8.59 | |||||
| ROIC % | 11.33 | |||||
| ROC (Joel Greenblatt) % | 68.67 | |||||
| ROCE % | 13.51 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 13.37 | |||||
| Forward PE Ratio | 14 | |||||
| PE Ratio without NRI | 13.56 | |||||
| Shiller PE Ratio | 20.65 | |||||
| Price-to-Owner-Earnings | 18.61 | |||||
| PEG Ratio | 0.71 | |||||
| PS Ratio | 1.54 | |||||
| PB Ratio | 2.23 | |||||
| Price-to-Free-Cash-Flow | 15.83 | |||||
| Price-to-Operating-Cash-Flow | 11.75 | |||||
| EV-to-EBIT | 11.7 | |||||
| EV-to-Forward-EBIT | 12.49 | |||||
| EV-to-EBITDA | 9.16 | |||||
| EV-to-Forward-EBITDA | 10.69 | |||||
| EV-to-Revenue | 1.84 | |||||
| EV-to-Forward-Revenue | 1.88 | |||||
| EV-to-FCF | 19.11 | |||||
| Price-to-Projected-FCF | 0.9 | |||||
| Price-to-DCF (Earnings Based) | 0.53 | |||||
| Price-to-DCF (FCF Based) | 0.68 | |||||
| Price-to-Median-PS-Value | 0.99 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.61 | |||||
| Earnings Yield (Greenblatt) % | 8.55 | |||||
| Forward Rate of Return (Yacktman) % | 26.18 |
